[{"address1": "22 Einstein Street", "address2": "Floor 4", "city": "Ness Ziona", "zip": "7414003", "country": "Israel", "phone": "972 7 2394 2377", "website": "https://www.biomx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.", "fullTimeEmployees": 58, "maxAge": 86400, "priceHint": 4, "previousClose": 0.3313, "open": 0.344, "dayLow": 0.3247, "dayHigh": 0.35, "regularMarketPreviousClose": 0.3313, "regularMarketOpen": 0.344, "regularMarketDayLow": 0.3247, "regularMarketDayHigh": 0.35, "beta": 1.319, "volume": 57699, "regularMarketVolume": 57699, "averageVolume": 214030, "averageVolume10days": 84580, "averageDailyVolume10Day": 84580, "bidSize": 1000, "askSize": 4000, "marketCap": 23231570, "fiftyTwoWeekLow": 0.187, "fiftyTwoWeekHigh": 0.855, "fiftyDayAverage": 0.35442, "twoHundredDayAverage": 0.32554, "currency": "USD", "enterpriseValue": 22768584, "floatShares": 40858407, "sharesOutstanding": 69806400, "sharesShort": 523588, "sharesShortPriorMonth": 155069, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0087, "heldPercentInsiders": 0.26829, "heldPercentInstitutions": 0.24103001, "shortRatio": 2.65, "shortPercentOfFloat": 0.0104, "impliedSharesOutstanding": 69806400, "bookValue": -0.159, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -37135000, "trailingEps": -0.59, "enterpriseToEbitda": -0.937, "52WeekChange": 0.110000014, "SandP52WeekChange": 0.26238096, "exchange": "ASE", "quoteType": "EQUITY", "symbol": "PHGE", "underlyingSymbol": "PHGE", "shortName": "BiomX Inc.", "longName": "BiomX Inc.", "firstTradeDateEpochUtc": 1552483800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "79f496b8-a482-326c-9356-662c9a6d1300", "messageBoardId": "finmb_430935769", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.3328, "recommendationKey": "none", "totalCash": 43007000, "totalCashPerShare": 0.616, "ebitda": -24307000, "totalDebt": 10124000, "quickRatio": 4.237, "currentRatio": 4.399, "debtToEquity": 44.256, "returnOnAssets": -0.25591, "returnOnEquity": -1.9032899, "freeCashflow": -11225750, "operatingCashflow": -27597000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]